Neuren Pharmaceuticals Ltd (NEU) - Total Assets

Latest as of June 2025: AU$331.25 Million AUD ≈ $234.38 Million USD

Based on the latest financial reports, Neuren Pharmaceuticals Ltd (NEU) holds total assets worth AU$331.25 Million AUD (≈ $234.38 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Neuren Pharmaceuticals Ltd - Total Assets Trend (2000–2024)

This chart illustrates how Neuren Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. Also see market cap of Neuren Pharmaceuticals Ltd for the company's overall valuation and market capitalisation.

Neuren Pharmaceuticals Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Neuren Pharmaceuticals Ltd's total assets of AU$331.25 Million consist of 97.5% current assets and 2.5% non-current assets. Review NEU total debt and obligations to assess the company's total debt and financial obligations.

Asset Category	Amount (AUD)	% of Total Assets
Cash & Equivalents	AU$0.00	0.8%
Accounts Receivable	AU$172.91 Million	42.2%
Inventory	AU$0.00	0.0%
Property, Plant & Equipment	AU$31.00K	0.0%
Intangible Assets	AU$0.00	0.0%
Goodwill	AU$0.00	0.0%

Asset Composition Trend (2000–2024)

This chart illustrates how Neuren Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See NEU live share price for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Neuren Pharmaceuticals Ltd's current assets represent 97.5% of total assets in 2024, an increase from 0.0% in 2000.
Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 89.6% in 2000.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
Asset Diversification: The largest asset category is accounts receivable at 42.2% of total assets.

Neuren Pharmaceuticals Ltd Competitors by Total Assets

Key competitors of Neuren Pharmaceuticals Ltd based on total assets are shown below.

Company	Country	Total Assets
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	USA	$2.19 Billion
Halozyme Therapeutics Inc NASDAQ:HALO	USA	$2.22 Billion
Tubize-Fin BR:TUB	Belgium	€1.99 Billion
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP	USA	$458.98 Million
Galecto Inc NASDAQ:GLTO	USA	$535.44 Million
Chengdu Kanghua Biological Products SHE:300841	China	CN¥3.94 Billion
Guangzhou Boji Medical and Biotechnological Co Ltd SHE:300404	China	CN¥1.67 Billion

Neuren Pharmaceuticals Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	40.42	25.42	16.11
Quick Ratio	40.42	25.42	16.11
Cash Ratio	0.75	0.29	15.26
Working Capital	AU$312.32 Million	AU$219.07 Million	AU$9.08 Million

Neuren Pharmaceuticals Ltd - Advanced Valuation Insights

This section examines the relationship between Neuren Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	5.29
Latest Market Cap to Assets Ratio	4.15
Asset Growth Rate (YoY)	65.2%
Total Assets	AU$409.71 Million
Market Capitalization	$1.70 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values Neuren Pharmaceuticals Ltd's assets at a significant premium (4.15x), suggesting investors see substantial growth potential or unique competitive advantages.

Rapid Asset Growth: Neuren Pharmaceuticals Ltd's assets grew by 65.2% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Neuren Pharmaceuticals Ltd (2000–2024)

The table below shows the annual total assets of Neuren Pharmaceuticals Ltd from 2000 to 2024.

Year	Total Assets	Change
2024-12-31	AU$409.71 Million ≈ $289.89 Million	+65.22%
2023-12-31	AU$247.97 Million ≈ $175.45 Million	+473.12%
2022-12-31	AU$43.27 Million ≈ $30.61 Million	+8.02%
2021-12-31	AU$40.06 Million ≈ $28.34 Million	+60.53%
2020-12-31	AU$24.95 Million ≈ $17.66 Million	+73.21%
2019-12-31	AU$14.41 Million ≈ $10.19 Million	-45.93%
2018-12-31	AU$26.64 Million ≈ $18.85 Million	+48.47%
2017-12-31	AU$17.94 Million ≈ $12.70 Million	+188.95%
2016-12-31	AU$6.21 Million ≈ $4.39 Million	-63.26%
2015-12-31	AU$16.90 Million ≈ $11.96 Million	-23.53%
2014-12-31	AU$22.11 Million ≈ $15.64 Million	-16.31%
2013-12-31	AU$26.41 Million ≈ $18.69 Million	+211.41%
2012-12-31	AU$8.48 Million ≈ $6.00 Million	-23.84%
2011-12-31	AU$11.14 Million ≈ $7.88 Million	+94.79%
2010-12-31	AU$5.72 Million ≈ $4.05 Million	-44.41%
2009-12-31	AU$10.28 Million ≈ $7.28 Million	+20.37%
2008-12-31	AU$8.54 Million ≈ $6.05 Million	-41.42%
2007-12-31	AU$14.59 Million ≈ $10.32 Million	-25.29%
2006-12-31	AU$19.52 Million ≈ $13.81 Million	-44.54%
2005-12-31	AU$35.20 Million ≈ $24.91 Million	+171.60%
2004-12-31	AU$12.96 Million ≈ $9.17 Million	+1762.35%
2003-12-31	AU$696.00K ≈ $492.46K	-79.11%
2002-12-31	AU$3.33 Million ≈ $2.36 Million	-35.29%
2001-12-31	AU$5.15 Million ≈ $3.64 Million	+12.33%
2000-12-31	AU$4.58 Million ≈ $3.24 Million	--

About Neuren Pharmaceuticals Ltd

AU:NEU Australia Biotechnology

Market Cap

$1.82 Billion

AU$2.57 Billion AUD

Market Cap Rank

#6792 Global

#160 in Australia

Share Price

AU$20.33

Change (1 day)

-1.17%

52-Week Range

AU$11.28 - AU$23.64

All Time High

AU$25.11